I have already answered you about these topics. See, please, Rossi-Blog Comment Discussion
I do not see how you get that figure. You seem to assume-wrongly- that the ecat was the only thing IH had in its portfolio that was worth Woodford's investment. That is clearly not the case. You can see how their evaluate of IH more than doubled after they returned the IP to Rossi who evidently was considered by them as a liability. Their evaluation has climbed faster without Rossi than with it. And your claim that ICCF would have folded without Rossi is clearly wrong since at ICCF21 there was no mention or papers based on Rossi's claims. You just keep pushing a clearly false narrative.